Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Alcohol-ROC-Training trial is studying whether a brief training program can help young adults who struggle with binge drinking and heavy drinking. The training focuses on techniques to control cravings for alcohol and includes two main approaches: cognitive-behavioral therapy (CBT), which helps change harmful thinking patterns, and mindfulness-based therapy (MBT), which encourages staying present in the moment. Participants will undergo a screening process to see if they qualify, followed by training sessions and assessments to track their progress.
To be eligible for this study, participants must be young adults aged 18 to 26 who have had at least three heavy drinking days in the past month and are motivated to cut down on their alcohol use. They should also be comfortable using a computer and smartphone, and able to commit to the study's schedule. Those who are dealing with severe alcohol or substance use disorders, serious mental health issues, or certain medical conditions will not be eligible. If you choose to participate, you can expect to attend several training sessions, complete assessments before and after the program, and have follow-up check-ins. This study aims to provide effective strategies for reducing alcohol consumption and improving overall well-being for young adults.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (1) Young adults ages 18-26 years, who (2) report ≥ 3 heavy drinking days (i.e., heavy drinking defined by \>3 drinks for women, \>4 drinks for men) in the prior month; (3) are motivated to quit or reduce drinking; (4) are fluent in English and have a 6th grade or higher reading level; (5) have access to a computer with working internet; (6) use a working smartphone; (7) can commit to the full length of the protocol; and (8) are willing to be randomized to intervention condition.
- Exclusion Criteria:
- • (1) Current (past 12 months) clinically-severe alcohol use disorder (AUD; e.g., history of seizures, delirium, or hallucinations during withdrawal) or current severe alcohol withdrawal; (2) Current (past 12 months) clinically-severe substance use disorder (except tobacco) or current severe drug withdrawal; (3) serious other psychiatric illness by history or examination; (4) severe or unstable physical disease within the past 6 months; (5) psychoactive medications (e.g., mood stabilizers) that have not been at a stable dose unless determined to be on a stable dose of medication by the study psychiatrist; (6) current use of any investigational medication; (7) color blindness; (8) biological females who are pregnant; and (9) notable dislike to any particular type of alcoholic beverage depicted in study stimuli; (10) Participants who will not complete at least 70% of past day EMA reports in the pre-intervention phase will not be randomized; (11) Participants who cannot understand or follow study-related instructions (e.g., unable to correctly use the intervention strategies, indicate lack of understanding of study instructions despite multiple attempts).
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Patients applied
Trial Officials
Hedy Kober, Ph.D.
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials